[Cervical dilatation by use of a vaginal suppository of meteneprost before voluntary interruption of the pregnancy in the first trimester]

J Gynecol Obstet Biol Reprod (Paris). 1987;16(5):637-42.
[Article in French]

Abstract

Instrumental dilatation of the cervix prior to first trimester absorption may be difficult and source of complications. Pharmacological dilatation is proposed in a prospective random study using vaginal suppository containing 10 mg of 9-deoxo, 16-16 dimethyl, 9 methylene PGE2 (Meteneprost). Mean cervical dilatation, 3 hours after treatment, was significantly higher in the treated group (8.1 vs 6 mm) and additional dilatation was facilitated by cervical softening. Side effects occurred in most of the treated patients (uterine pain) but on a minor scale. This procedure may be considered as effective, safe and easy.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • 16,16-Dimethylprostaglandin E2 / administration & dosage
  • 16,16-Dimethylprostaglandin E2 / analogs & derivatives
  • 16,16-Dimethylprostaglandin E2 / therapeutic use*
  • Abortifacient Agents / therapeutic use*
  • Abortifacient Agents, Nonsteroidal / administration & dosage
  • Abortifacient Agents, Nonsteroidal / therapeutic use*
  • Abortion, Therapeutic*
  • Administration, Intravaginal
  • Adolescent
  • Adult
  • Female
  • Humans
  • Pregnancy
  • Pregnancy Trimester, First
  • Prostaglandins E, Synthetic / therapeutic use*
  • Random Allocation
  • Vacuum Curettage

Substances

  • Abortifacient Agents
  • Abortifacient Agents, Nonsteroidal
  • Prostaglandins E, Synthetic
  • meteneprost
  • 16,16-Dimethylprostaglandin E2